Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction (RESPECT-HF)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 144 participants.

Also called NCT02041130

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 144 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02041130
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, New Zealand, Singapore (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02041130. Randomized; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction (RESPECT-HF)
Acronym
RESPECT-HF
Condition
Heart Failure
Intervention (Device)
Renal Denervation
Lead sponsor
National University Hospital, Singapore (class: other)
Collaborator
University of Otago (class: other)
Collaborator
Wellington Hospital (class: other government)
Collaborator
University of Auckland, New Zealand (class: other)
Collaborator
Monash University (class: other)
Collaborator
Tan Tock Seng Hospital (class: other)
Collaborator
Changi General Hospital (class: other)
Collaborator
Singapore Clinical Research Institute (class: other)

Record details

Record id
cardio:ct-nct02041130
Content hash
5f0eb453a7663a9915c65ea0d5b9e1cc17b297a93a1e01c022343614b1cc1a0a